;PMID: 9103974
;source_file_986.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)sentence:[e:51..138] = [t:51..138]
;2)section:[e:142..215] = [t:142..215]
;3)section:[e:219..342] = [t:219..342]
;4)sentence:[e:346..445] = [t:346..445]
;5)sentence:[e:446..679] = [t:446..679]
;6)sentence:[e:680..879] = [t:680..879]
;7)sentence:[e:880..975] = [t:880..975]
;8)sentence:[e:977..1297] = [t:977..1297]
;9)section:[e:1301..1345] = [t:1301..1345]

;section 0 Span:0..45
;FEMS Microbiol Lett. 1997 Apr 1;149(1):25-30.
(SEC
  (FRAG (NNP:[0..4] FEMS) (NNP:[5..14] Microbiol) (NNP:[15..19] Lett)
        (.:[19..20] .) (CD:[21..25] 1997) (NNP:[26..29] Apr)
        (CD:[30..36] 1;149-LRB-) (CD:[36..37] 1) (-RRB-:[37..38] -RRB-)
        (CD:[38..41] :25) (::[41..42] -) (CD:[42..44] 30) (.:[44..45] .)))

;sentence 1 Span:51..138
;Differential inhibition of Candida albicans CYP51 with azole antifungal 
;stereoisomers.
;[95..100]:cyp450:"CYP51"
;[106..137]:substance:"azole antifungal  stereoisomers"
(SENT
  (NP-HLN
    (NP (JJ:[51..63] Differential) (NN:[64..74] inhibition))
    (PP (IN:[75..77] of)
      (NP
        (NML (NNP:[78..85] Candida) (NNP:[86..94] albicans))
        (NN:[95..100] CYP51)))
    (PP (IN:[101..105] with)
      (NP (NN:[106..111] azole) (JJ:[112..122] antifungal)
          (NNS:[124..137] stereoisomers)))
    (.:[137..138] .)))

;section 2 Span:142..215
;Lamb DC, Kelly DE, Baldwin BC, Gozzo F, Boscott P, Richards WG, Kelly SL.
(SEC
  (FRAG (NNP:[142..146] Lamb) (NNP:[147..149] DC) (,:[149..150] ,)
        (NNP:[151..156] Kelly) (NNP:[157..159] DE) (,:[159..160] ,)
        (NNP:[161..168] Baldwin) (NNP:[169..171] BC) (NNP:[171..172] ,)
        (NNP:[173..178] Gozzo) (NNP:[179..180] F) (,:[180..181] ,)
        (DT:[182..189] Boscott) (NNP:[190..191] P) (,:[191..192] ,)
        (NNP:[193..201] Richards) (NNP:[202..204] WG) (,:[204..205] ,)
        (NNP:[206..211] Kelly) (NNP:[212..215] SL.)))

;section 3 Span:219..342
;Krebs Institute for Biomolecular Research, Department of Molecular Biology
;and  Biotechnology, University of Sheffield, UK.
(SEC
  (FRAG (NNP:[219..224] Krebs) (NNP:[225..234] Institute) (IN:[235..238] for)
        (NNP:[239..251] Biomolecular) (NNP:[252..260] Research) (,:[260..261] ,)
        (NNP:[262..272] Department) (IN:[273..275] of)
        (NNP:[276..285] Molecular) (NNP:[286..293] Biology) (CC:[294..297] and)
        (NNP:[299..312] Biotechnology) (,:[312..313] ,)
        (NNP:[314..324] University) (IN:[325..327] of)
        (NNP:[328..337] Sheffield) (,:[337..338] ,) (NNP:[339..342] UK.)))

;sentence 4 Span:346..445
;Azole antifungal compounds are important in agriculture and in the treatment
;of  mycotic infection.
;[346..372]:substance:"Azole antifungal compounds"
(SENT
  (S
    (NP-SBJ (NN:[346..351] Azole) (JJ:[352..362] antifungal)
            (NNS:[363..372] compounds))
    (VP (VBP:[373..376] are)
      (ADJP-PRD (JJ:[377..386] important))
      (PP
        (PP (IN:[387..389] in)
          (NP (NN:[390..401] agriculture)))
        (CC:[402..405] and)
        (PP (IN:[406..408] in)
          (NP
            (NP (DT:[409..412] the) (NN:[413..422] treatment))
            (PP (IN:[423..425] of)
              (NP (JJ:[427..434] mycotic) (NN:[435..444] infection)))))))
    (.:[444..445] .)))

;sentence 5 Span:446..679
;The target enzyme, sterol 14 alpha-demethylase (CYP51), is  inhibited through
;binding of triazole N-4 to the haem of this P450, as a sixth  ligand together
;with the N-1 substituent groups interacting in some way with the 
;apoprotein.
;[457..463]:cyp450:"enzyme"
;[465..492]:cyp450:"sterol 14 alpha-demethylase"
;[494..499]:cyp450:"CYP51"
;[535..547]:substance:"triazole N-4"
;[568..572]:cyp450:"P450"
;[611..614]:substance:"N-1"
;[668..678]:substance:"apoprotein"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[446..449] The) (NN:[450..456] target) (NN:[457..463] enzyme))
      (,:[463..464] ,)
      (NP
        (NP (NN:[465..471] sterol) (CD:[472..474] 14)
            (NN:[475..492] alpha-demethylase))
        (NP (-LRB-:[493..494] -LRB-) (NN:[494..499] CYP51)
            (-RRB-:[499..500] -RRB-))))
    (,:[500..501] ,)
    (VP (VBZ:[502..504] is)
      (VP (VBN:[506..515] inhibited)
        (NP-1 (-NONE-:[515..515] *))
        (PP-MNR (IN:[516..523] through)
          (NP
            (NP (VBG:[524..531] binding))
            (PP (IN:[532..534] of)
              (NP (NN:[535..543] triazole) (NN:[544..547] N-4)))
            (PP (TO:[548..550] to)
              (NP
                (NP (DT:[551..554] the) (NN:[555..559] haem))
                (PP (IN:[560..562] of)
                  (NP (DT:[563..567] this) (NN:[568..572] P450)))))
            (,:[572..573] ,)
            (PP (IN:[574..576] as)
              (NP
                (NP (DT:[577..578] a) (JJ:[579..584] sixth)
                    (NN:[586..592] ligand))
                (PP (RB:[593..601] together) (IN:[602..606] with)
                  (NP
                    (NP (DT:[607..610] the) (NN:[611..614] N-1)
                        (NN:[615..626] substituent) (NNS:[627..633] groups))
                    (VP (VBG:[634..645] interacting)
                      (PP-MNR (IN:[646..648] in)
                        (NP (DT:[649..653] some) (NN:[654..657] way)))
                      (PP-CLR (IN:[658..662] with)
                        (NP (DT:[663..666] the) (NN:[668..678] apoprotein))))))))))))
    (.:[678..679] .)))

;sentence 6 Span:680..879
;Here we use Saccharomyces cerevisiae expression systems for the  target
;enzyme of Candida albicans to investigate binding of enantiomers of the 
;azole antifungal compounds SCH39304 and tetraconazole.
;[752..758]:substance:"enzyme"
;[805..816]:substance:"enantiomers"
;[825..830]:substance:"azole"
;[842..851]:substance:"compounds"
;[852..860]:substance:"SCH39304"
;[865..878]:substance:"tetraconazole"
(SENT
  (S
    (ADVP (RB:[680..684] Here))
    (NP-SBJ-1 (PRP:[685..687] we))
    (VP (VBP:[688..691] use)
      (NP
        (NML (NNP:[692..705] Saccharomyces) (NNP:[706..716] cerevisiae))
        (NN:[717..727] expression) (NNS:[728..735] systems))
      (PP (IN:[736..739] for)
        (NP
          (NP (DT:[740..743] the) (NN:[745..751] target) (NN:[752..758] enzyme))
          (PP (IN:[759..761] of)
            (NP (NNP:[762..769] Candida) (NNP:[770..778] albicans)))))
      (S-PRP
        (NP-SBJ-1 (-NONE-:[778..778] *))
        (VP (TO:[779..781] to)
          (VP (VB:[782..793] investigate)
            (NP
              (NP (VBG:[794..801] binding))
              (PP (IN:[802..804] of)
                (NP
                  (NP (NNS:[805..816] enantiomers))
                  (PP (IN:[817..819] of)
                    (NP
                      (NP (DT:[820..823] the) (NN:[825..830] azole)
                          (JJ:[831..841] antifungal) (NNS:[842..851] compounds))
                      (NP (NN:[852..860] SCH39304) (CC:[861..864] and)
                          (NN:[865..878] tetraconazole)))))))))))
    (.:[878..879] .)))

;sentence 7 Span:880..975
;A molecular model  produced previously provided qualitative explanations for
;these differences.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[880..881] A) (JJ:[882..891] molecular) (NN:[892..897] model))
      (VP (VBN:[899..907] produced)
        (NP (-NONE-:[907..907] *))
        (ADVP-TMP (RB:[908..918] previously))))
    (VP (VBD:[919..927] provided)
      (NP (JJ:[928..939] qualitative) (NNS:[940..952] explanations))
      (PP (IN:[953..956] for)
        (NP (DT:[957..962] these) (NNS:[963..974] differences))))
    (.:[974..975] .)))

;sentence 8 Span:977..1297
;Interaction of the azole antifungal aromatic group with Phe-233 or -235 may 
;cause the higher activity for (R)-tetraconazole while inactivity of the 
;(SS)-enantiomer of SCH39304 was predicted to result from incompatibility of
;the  hydrophilic sulfonyl moiety when located into the hydrophobic pocket of
;the  active site.
;[996..1001]:substance:"azole"
;[1013..1021]:substance:"aromatic"
;[1033..1040]:substance:"Phe-233"
;[1033..1036]...[1044..1048]:substance:"Phe"..."-235"
;[1084..1101]:substance:"(R)-tetraconazole"
;[1127..1142]:substance:"(SS)-enantiomer"
;[1146..1154]:substance:"SCH39304"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[977..988] Interaction))
      (PP (IN:[989..991] of)
        (NP (DT:[992..995] the) (NN:[996..1001] azole)
            (JJ:[1002..1012] antifungal) (JJ:[1013..1021] aromatic)
            (NN:[1022..1027] group)))
      (PP (IN:[1028..1032] with)
        (NP
          (NP
            (NML-3 (NN:[1033..1036] Phe))
            (HYPH:[1036..1037] -) (CD:[1037..1040] 233))
          (CC:[1041..1043] or)
          (NP
            (NML-3 (-NONE-:[1043..1043] *P*))
            (HYPH:[1044..1045] -) (CD:[1045..1048] 235)))))
    (VP (MD:[1049..1052] may)
      (VP (VB:[1054..1059] cause)
        (NP
          (NP (DT:[1060..1063] the) (JJR:[1064..1070] higher)
              (NN:[1071..1079] activity))
          (PP (IN:[1080..1083] for)
            (NP (NN:[1084..1101] -LRB-R-RRB--tetraconazole)))))
      (SBAR-ADV (IN:[1102..1107] while)
        (S
          (NP-SBJ-2
            (NP (NN:[1108..1118] inactivity))
            (PP (IN:[1119..1121] of)
              (NP
                (NP (DT:[1122..1125] the)
                    (NN:[1127..1142] -LRB-SS-RRB--enantiomer))
                (PP (IN:[1143..1145] of)
                  (NP (NN:[1146..1154] SCH39304))))))
          (VP (VBD:[1155..1158] was)
            (VP (VBN:[1159..1168] predicted)
              (S
                (NP-SBJ-2 (-NONE-:[1168..1168] *))
                (VP (TO:[1169..1171] to)
                  (VP (VB:[1172..1178] result)
                    (PP-CLR (IN:[1179..1183] from)
                      (NP
                        (NP (NN:[1184..1199] incompatibility))
                        (PP (IN:[1200..1202] of)
                          (NP-4 (DT:[1203..1206] the)
                                (JJ:[1208..1219] hydrophilic)
                                (NN:[1220..1228] sulfonyl)
                                (NN:[1229..1235] moiety)))))
                    (SBAR-TMP
                      (WHADVP-1 (WRB:[1236..1240] when))
                      (S
                        (NP-SBJ-4 (-NONE-:[1240..1240] *))
                        (VP (VBN:[1241..1248] located)
                          (NP-4 (-NONE-:[1248..1248] *))
                          (ADVP-TMP-1 (-NONE-:[1248..1248] *T*))
                          (PP (IN:[1249..1253] into)
                            (NP
                              (NP (DT:[1254..1257] the)
                                  (JJ:[1258..1269] hydrophobic)
                                  (NN:[1270..1276] pocket))
                              (PP (IN:[1277..1279] of)
                                (NP (DT:[1280..1283] the)
                                    (JJ:[1285..1291] active)
                                    (NN:[1292..1296] site))))))))))))))))
    (.:[1296..1297] .)))

;section 9 Span:1301..1345
;PMID: 9103974 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1301..1305] PMID) (::[1305..1306] :) (CD:[1307..1314] 9103974)
        (IN:[1315..1316] -LSB-) (NNP:[1316..1322] PubMed) (HYPH:[1323..1324] -)
        (JJ:[1325..1332] indexed) (IN:[1333..1336] for)
        (NNP:[1337..1345] MEDLINE-RSB-)))
